Bio-Rad Laboratories (BIO-B) Operating Leases (2019 - 2026)

Bio-Rad Laboratories (BIO-B) has 8 years of Operating Leases data on file, last reported at $138.6 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $138.6 million, down 17.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $138.6 million (down 17.3% YoY), and the FY2025 annual result was $145.7 million, up 10.88% from the prior year.
• Operating Leases slipped to $138.6 million in Q1 2026 per BIO-B's latest filing, from $145.7 million in the prior quarter.
• Over five years, Operating Leases peaked at $206.3 million in Q3 2023 and troughed at $131.4 million in Q4 2024.
• A 5-year average of $173.8 million and a median of $183.1 million in 2023 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2024: Operating Leases surged 40.15% in 2023, then plunged 30.24% in 2024.
• A 5-year view of Operating Leases shows it stood at $189.9 million in 2022, then slipped by 12.85% to $165.5 million in 2023, then slipped by 20.6% to $131.4 million in 2024, then grew by 10.88% to $145.7 million in 2025, then declined by 4.87% to $138.6 million in 2026.
• Business Quant data shows BIO-B's Operating Leases at $138.6 million in Q1 2026, $145.7 million in Q4 2025, and $192.6 million in Q3 2025.